Across TCGA pan-cancer cohorts, AHSA2P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AHSA2P data layer compared with 23 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AHSA2P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AHSA2P expression acts as an unfavorable survival marker.
UCEC are the cancer types where AHSA2P Mutation most reproducibly stratifies survival.